This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.02.049v1 49/23/2231    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (33) Citing Articles via Google Scholar Google Scholar Articles by Marcoff, L. Articles by Thompson, P. D. Search for Related Content PubMed Articles by Marcoff, L. Articles by Thompson, P. D.

STATE-OF-THE-ART PAPER

The Role of Coenzyme Q10 in Statin-Associated Myopathy

A Systematic Review

Leo Marcoff, MD^_* and Paul D. Thompson, MD^,,a,_*

^_* Section of Cardiology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
Hartford Hospital, Hartford, Connecticut
University of Connecticut, Farmington, Connecticut.

Manuscript received November 27, 2006; revised manuscript received January 29, 2007, accepted February 5, 2007.

^_* Reprint requests and correspondence: Dr. Paul D. Thompson, Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, Connecticut 06102. (Email: pthomps{at}harthosp.org).

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are currently the most effective medications for reducing low-density lipoprotein cholesterol concentrations. Although generally safe, they have been associated with a variety of myopathic complaints. Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis of ubiquinone or coenzyme Q10 (CoQ10). This fact, plus the role of CoQ10 in mitochondrial energy production, has prompted the hypothesis that statin-induced CoQ10 deficiency is involved in the pathogenesis of statin myopathy. We identified English language articles relating statin treatment and CoQ10 levels via a PubMed search through August 2006. Abstracts were reviewed and articles addressing the relationship between statin treatment and CoQ10 levels were examined in detail. Statin treatment reduces circulating levels of CoQ10. The effect of statin therapy on intramuscular levels of CoQ10 is not clear, and data on intramuscular CoQ10 levels in symptomatic patients with statin-associated myopathy are scarce. Mitochondrial function may be impaired by statin therapy, and this effect may be exacerbated by exercise. Supplementation can raise the circulating levels of CoQ10, but data on the effect of CoQ10 supplementation on myopathic symptoms are scarce and contradictory. We conclude that there is insufficient evidence to prove the etiologic role of CoQ10 deficiency in statin-associated myopathy and that large, well-designed clinical trials are required to address this issue. The routine use of CoQ10 cannot be recommended in statin-treated patients. Nevertheless, there are no known risks to this supplement and there is some anecdotal and preliminary trial evidence of its effectiveness. Consequently, CoQ10 can be tested in patients requiring statin treatment, who develop statin myalgia, and who cannot be satisfactorily treated with other agents. Some patients may respond, if only via a placebo effect.

Abbreviations and Acronyms   CK = creatine kinase   CoQ10 = coenzyme Q10   HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A   LDL = low-density lipoprotein   RER = respiratory exchange ratio   O 2 max = maximal oxygen uptake

This article has been cited by other articles:

				N. Sumien, K. R. Heinrich, R. A. Shetty, R. S. Sohal, and M. J. Forster Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice J. Nutr., October 1, 2009; 139(10): 1926 - 1932. [Abstract] [Full Text] [PDF]

				P. Cao, J.-i. Hanai, P. Tanksale, S. Imamura, V. P. Sukhatme, and S. H. Lecker Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect FASEB J, September 1, 2009; 23(9): 2844 - 2854. [Abstract] [Full Text] [PDF]

				D. J. Becker, R. Y. Gordon, S. C. Halbert, B. French, P. B. Morris, and D. J. Rader Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial Ann Intern Med, June 16, 2009; 150(12): 830 - 839. [Abstract] [Full Text] [PDF]

				T. R. Joy and R. A. Hegele Narrative Review: Statin-Related Myopathy Ann Intern Med, June 16, 2009; 150(12): 858 - 868. [Abstract] [Full Text] [PDF]

				G. W. Allison, R. J. Perla, P. P. Belliveau, and S. M. Angelis Elevated creatine phosphokinase levels associated with linezolid therapy Am. J. Health Syst. Pharm., June 15, 2009; 66(12): 1097 - 1100. [Abstract] [Full Text] [PDF]

				K. Chatham, C. M Gelder, T. A Lines, and L. P Cahalin Suspected Statin-Induced Respiratory Muscle Myopathy During Long-Term Inspiratory Muscle Training in a Patient With Diaphragmatic Paralysis Physical Therapy, March 1, 2009; 89(3): 257 - 266. [Abstract] [Full Text] [PDF]

				T. A. Jacobson Toward 'Pain-Free' Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia Mayo Clin. Proc., June 1, 2008; 83(6): 687 - 700. [Abstract] [Full Text] [PDF]

				J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J. G.F. Cleland, J. H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, et al. Rosuvastatin in Older Patients with Systolic Heart Failure N. Engl. J. Med., November 29, 2007; 357(22): 2248 - 2261. [Abstract] [Full Text] [PDF]

				H. Wolinsky Coenzyme Q10 in Statin-Associated Myopathy J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1911 - 1911. [Full Text] [PDF]

				L. Marcoff and P. D. Thompson Reply J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1911 - 1911. [Full Text] [PDF]